Cargando…
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial
BACKGROUND: The Vaxxas high-density microarray patch (HD-MAP) consists of a high density of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) offer the possibility of improved vaccine thermostability as well as the potential to be safer, more acceptable, easi...
Autores principales: | Forster, Angus H., Witham, Katey, Depelsenaire, Alexandra C. I., Veitch, Margaret, Wells, James W., Wheatley, Adam, Pryor, Melinda, Lickliter, Jason D., Francis, Barbara, Rockman, Steve, Bodle, Jesse, Treasure, Peter, Hickling, Julian, Fernando, Germain J. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077342/ https://www.ncbi.nlm.nih.gov/pubmed/32181756 http://dx.doi.org/10.1371/journal.pmed.1003024 |
Ejemplares similares
-
Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial
por: Depelsenaire, Alexandra C. I., et al.
Publicado: (2021) -
M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
por: Mills, Jamie-Lee S., et al.
Publicado: (2020) -
Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
por: Mills, Jamie-Lee S., et al.
Publicado: (2020) -
Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis
por: Berger, Matthew N, et al.
Publicado: (2023) -
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial
por: Baker, Ben, et al.
Publicado: (2023)